Immune defence against EBV and EBV-associated disease

Current Opinion in Immunology

Volumn 23, Issue 2, 2011, Pages 258-264

  Long, Heather M ^a   Taylor, Graham S ^a   Rickinson, Alan B ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; INTERLEUKIN 7 RECEPTOR; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN EXPRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL SURVIVAL; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DRUG TARGETING; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE LOCUS; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOTHERAPY; INNATE IMMUNITY; NASOPHARYNX CARCINOMA; NONHUMAN; REVIEW; T LYMPHOCYTE; VACCINATION;

ANIMALS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS; HUMANS; NEOPLASMS; T-LYMPHOCYTES; VIRUS INTERNALIZATION;

EID: 79953068030     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.12.014     Document Type: Review

References (79)

1. Hislop A.D., Taylor G.S., Sauce D., Rickinson A.B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007, 25:587-617.
2. Greenough T.C., Campellone S.C., Brody R., Jain S., Sanchez-Merino V., Somasundaran M., Luzuriaga K. Programmed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usage. PLoS One 2010, 5:e12926.
3. Sauce D., Larsen M., Abbott R.J., Hislop A.D., Leese A.M., Khan N., Papagno L., Freeman G.J., Rickinson A.B. Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infection. J Virol 2009, 83:9068-9078.
4. Scherrenburg J., Piriou E.R., Nanlohy N.M., van Baarle D. Detailed analysis of Epstein-Barr virus-specific CD4+ and CD8+ T cell responses during infectious mononucleosis. Clin Exp Immunol 2008, 153:231-239.
5. Adhikary D., Behrends U., Moosmann A., Witter K., Bornkamm G.W., Mautner J. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 2006, 203:995-1006.
6. Merlo A., Turrini R., Bobisse S., Zamarchi R., Alaggio R., Dolcetti R., Mautner J., Zanovello P., Amadori A., Rosato A. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors. J Immunol 2010, 184:5895-5902.
7. Strowig T., Brilot F., Arrey F., Bougras G., Thomas D., Muller W.A., Munz C. Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma. PLoS Pathog 2008, 4:e27.
8. Ma C.S., Nichols K.E., Tangye S.G. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu Rev Immunol 2007, 25:337-379.
9. Hislop A.D., Palendira U., Leese A.M., Arkwright P.D., Rohrlich P.S., Tangye S.G., Gaspar H.B., Lankester A.C., Moretta A., Rickinson A.B. Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood 2010, 116:3249-3257.
10. Snow A.L., Marsh R.A., Krummey S.M., Roehrs P., Young L.R., Zhang K., van Hoff J., Dhar D., Nichols K.E., Filipovich A.H., et al. Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J Clin Invest 2009, 119:2976-2989.
11. Ressing M.E., Horst D., Griffin B.D., Tellam J., Zuo J., Khanna R., Rowe M., Wiertz E.J. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin Cancer Biol 2008, 18:397-408.
12. Hislop A.D., Ressing M.E., van Leeuwen D., Pudney V.A., Horst D., Koppers-Lalic D., Croft N.P., Neefjes J.J., Rickinson A.B., Wiertz E.J. A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 2007, 204:1863-1873.
13. Horst D., van Leeuwen D., Croft N.P., Garstka M.A., Hislop A.D., Kremmer E., Rickinson A.B., Wiertz E.J., Ressing M.E. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J Immunol 2009, 182:2313-2324.
14. Croft N.P., Shannon-Lowe C., Bell A.I., Horst D., Kremmer E., Ressing M.E., Wiertz E.J., Middeldorp J.M., Rowe M., Rickinson A.B., et al. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog 2009, 5:e1000490.
15. Zuo J., Currin A., Griffin B.D., Shannon-Lowe C., Thomas W.A., Ressing M.E., Wiertz E.J., Rowe M. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog 2009, 5:e1000255.
16. Zuo J., Quinn L.L., Tamblyn J., Thomas W.A., Feederle R., Delecluse H.J., Hislop A.D., Rowe M. The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting MHC class I molecules trafficking on both the exocytic and endocytic pathways. J Virol 2010.
17. Zuo J., Thomas W., van Leeuwen D., Middeldorp J.M., Wiertz E.J., Ressing M.E., Rowe M. The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. J Virol 2008, 82:2385-2393.
18. Nachmani D., Stern-Ginossar N., Sarid R., Mandelboim O. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 2009, 5:376-385.
19. Li D., Qian L., Chen C., Shi M., Yu M., Hu M., Song L., Shen B., Guo N. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation. J Immunol 2009, 182:1799-1809.
20. Smith C., Wakisaka N., Crough T., Peet J., Yoshizaki T., Beagley L., Khanna R. Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation. Blood 2009, 113:6148-6152.
21. Lee D.Y., Sugden B. The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy. Oncogene 2008, 27:2833-2842.
22. Brooks J.M., Lee S.P., Leese A.M., Thomas W.A., Rowe M., Rickinson A.B. Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition. J Immunol 2009, 182:1919-1928.
23. Apcher S., Daskalogianni C., Manoury B., Fahraeus R. Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation. PLoS Pathog 2010, 6:e1001151.
24. Apcher S., Komarova A., Daskalogianni C., Yin Y., Malbert-Colas L., Fahraeus R. mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1. J Virol 2009, 83:1289-1298.
25. Tellam J., Smith C., Rist M., Webb N., Cooper L., Vuocolo T., Connolly G., Tscharke D.C., Devoy M.P., Khanna R. Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. Proc Natl Acad Sci U S A 2008, 105:9319-9324.
26. Mackay L.K., Long H.M., Brooks J.M., Taylor G.S., Leung C.S., Chen A., Wang F., Rickinson A.B. T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display. PLoS Pathog 2009, 5:e1000699.
27. Leung C.S., Haigh T.A., Mackay L.K., Rickinson A.B., Taylor G.S. Nuclear location of an endogenously expressed antigen. EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. Proc Natl Acad Sci U S A 2010, 107:2165-2170.
28. Heller K.N., Arrey F., Steinherz P., Portlock C., Chadburn A., Kelly K., Munz C. Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1. Int J Cancer 2008, 123:2824-2831.
29. Moormann A.M., Heller K.N., Chelimo K., Embury P., Ploutz-Snyder R., Otieno J.A., Oduor M., Munz C., Rochford R. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer 2009, 124:1721-1726.
30. Fogg M.H., Wirth L.J., Posner M., Wang F. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 2009, 106:3318-3323.
31. Lin X., Gudgeon N.H., Hui E.P., Jia H., Qun X., Taylor G.S., Barnardo M.C., Lin C.K., Rickinson A.B., Chan A.T. CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients. Cancer Immunol Immunother 2008, 57:963-975.
32. Diepstra A., Niens M., Vellenga E., van Imhoff G.W., Nolte I.M., Schaapveld M., van der Steege G., van den Berg A., Kibbelaar R.E., te Meerman G.J., et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet 2005, 365:2216-2224.
33. Niens M., Jarrett R.F., Hepkema B., Nolte I.M., Diepstra A., Platteel M., Kouprie N., Delury C.P., Gallagher A., Visser L., et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 2007, 110:3310-3315.
34. Hjalgrim H., Rostgaard K., Johnson P.C., Lake A., Shield L., Little A.M., Ekstrom-Smedby K., Adami H.O., Glimelius B., Hamilton-Dutoit S., et al. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proc Natl Acad Sci U S A 2010, 107:6400-6405.
35. Brennan R.M., Burrows S.R. A mechanism for the HLA-A*01-associated risk for EBV+ Hodgkin lymphoma and infectious mononucleosis. Blood 2008, 112:2589-2590.
36. McAulay K.A., Higgins C.D., Macsween K.F., Lake A., Jarrett R.F., Robertson F.L., Williams H., Crawford D.H. HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection. J Clin Invest 2007, 117:3042-3048.
37. Tse K.P., Su W.H., Chang K.P., Tsang N.M., Yu C.J., Tang P., See L.C., Hsueh C., Yang M.L., Hao S.P., et al. Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. Am J Hum Genet 2009, 85:194-203.
38. Bei J.X., Li Y., Jia W.H., Feng B.J., Zhou G., Chen L.Z., Feng Q.S., Low H.Q., Zhang H., He F., et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet 2010, 42:599-603.
39. Heslop H.E., Slobod K.S., Pule M.A., Hale G.A., Rousseau A., Smith C.A., Bollard C.M., Liu H., Wu M.F., Rochester R.J., et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935.
40. Haque T., McAulay K.A., Kelly D., Crawford D.H. Allogeneic T-cell therapy for Epstein-Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up. Transplantation 2010, 90:93-94.
41. Amir A.L., D'Orsogna L.J., Roelen D.L., van Loenen M.M., Hagedoorn R.S., de Boer R., van der Hoorn M.A., Kester M.G., Doxiadis I.I., Falkenburg J.H., et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010, 115:3146-3157.
42. Melenhorst J.J., Leen A.M., Bollard C.M., Quigley M.F., Price D.A., Rooney C.M., Brenner M.K., Barrett A.J., Heslop H.E. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 2010, 116:4700-4702.
43. Barker J.N., Doubrovina E., Sauter C., Jaroscak J.J., Perales M.A., Doubrovin M., Prockop S.E., Koehne G., O'Reilly R.J. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010, 116:5045-5049.
44. Stanevsky A., Goldstein G., Nagler A. Umbilical cord blood transplantation: pros, cons and beyond. Blood Rev 2009, 23:199-204.
45. Hanley P.J., Cruz C.R., Savoldo B., Leen A.M., Stanojevic M., Khalil M., Decker W., Molldrem J.J., Liu H., Gee A.P., et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009, 114:1958-1967.
46. Louis C.U., Straathof K., Bollard C.M., Ennamuri S., Gerken C., Lopez T.T., Huls M.H., Sheehan A., Wu M.F., Liu H., et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 2010, 33:983-990.
47. McAulay K.A., Haque T., Urquhart G., Bellamy C., Guiretti D., Crawford D.H. Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease. J Immunol 2009, 182:3892-3901.
48. Haque T., Wilkie G.M., Jones M.M., Higgins C.D., Urquhart G., Wingate P., Burns D., McAulay K., Turner M., Bellamy C., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110:1123-1131.
49. Adhikary D., Behrends U., Boerschmann H., Pfunder A., Burdach S., Moosmann A., Witter K., Bornkamm G.W., Mautner J. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. PLoS One 2007, 2:e583.
50. Taylor G.S., Long H.M., Haigh T.A., Larsen M., Brooks J., Rickinson A.B. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J Immunol 2006, 177:3746-3756.
51. Long H.M., Zuo J., Leese A.M., Gudgeon N.H., Jia H., Taylor G.S., Rickinson A.B. CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells. Blood 2009, 114:807-815.
52. Fox C.P., Haigh T.A., Taylor G.S., Long H.M., Lee S.P., Shannon-Lowe C., O'Connor S., Bollard C.M., Iqbal J., Chan W.C., et al. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood 2010, 116:3695-3704.
53. Haigh T.A., Lin X., Jia H., Hui E.P., Chan A.T., Rickinson A.B., Taylor G.S. EBV latent membrane proteins Niens M., 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. J Immunol 2008, 180:1643-1654.
54. Kobayashi H., Nagato T., Takahara M., Sato K., Kimura S., Aoki N., Azumi M., Tateno M., Harabuchi Y., Celis E. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res 2008, 68:901-908.
55. Demachi-Okamura A., Ito Y., Akatsuka Y., Tsujimura K., Morishima Y., Takahashi T., Kuzushima K. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells. Cancer Sci 2008, 99:1633-1642.
56. Uhlin M., Okas M., Gertow J., Uzunel M., Brismar T.B., Mattsson J. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother 2010, 59:473-477.
57. Jones K., Nourse J.P., Morrison L., Nguyen-Van D., Moss D.J., Burrows S.R., Gandhi M.K. Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood 2010, 116:2245-2252.
58. Moosmann A., Bigalke I., Tischer J., Schirrmann L., Kasten J., Tippmer S., Leeping M., Prevalsek D., Jaeger G., Ledderose G., et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010, 115:2960-2970.
59. Bollard C.M., Gottschalk S., Leen A.M., Weiss H., Straathof K.C., Carrum G., Khalil M., Wu M.F., Huls M.H., Chang C.C., et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007, 110:2838-2845.
60. Duraiswamy J., Bharadwaj M., Tellam J., Connolly G., Cooper L., Moss D., Thomson S., Yotnda P., Khanna R. Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res 2004, 64:1483-1489.
61. Lutzky V.P., Corban M., Heslop L., Morrison L.E., Crooks P., Hall D.F., Coman W.B., Thomson S.A., Moss D.J. Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine. J Virol 2010, 84:407-417.
62. Taylor G.S., Haigh T.A., Gudgeon N.H., Phelps R.J., Lee S.P., Steven N.M., Rickinson A.B. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol 2004, 78:768-778.
63. Vera J.F., Hoyos V., Savoldo B., Quintarelli C., Giordano Attianese G.M., Leen A.M., Liu H., Foster A.E., Heslop H.E., Rooney C.M., et al. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 2009, 17:880-888.
64. Hoyos V., Savoldo B., Quintarelli C., Mahendravada A., Zhang M., Vera J., Heslop H.E., Rooney C.M., Brenner M.K., Dotti G. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010, 24:1160-1170.
65. Louis C.U., Straathof K., Bollard C.M., Gerken C., Huls M.H., Gresik M.V., Wu M.F., Weiss H.L., Gee A.P., Brenner M.K., et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009, 113:2442-2450.
66. Yamamoto R., Nishikori M., Kitawaki T., Sakai T., Hishizawa M., Tashima M., Kondo T., Ohmori K., Kurata M., Hayashi T., et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008, 111:3220-3224.
67. Aldinucci D., Gloghini A., Pinto A., De Filippi R., Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010, 221:248-263.
68. Gandhi M.K., Wilkie G.M., Dua U., Mollee P.N., Grimmett K., Williams T., Whitaker N., Gill D., Crawford D.H. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant 2007, 7:1293-1299.
69. Smith C., Beagley L., Khanna R. Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression. J Virol 2009, 83:6192-6198.
70. Di Stasi A., De Angelis B., Rooney C.M., Zhang L., Mahendravada A., Foster A.E., Heslop H.E., Brenner M.K., Dotti G., Savoldo B. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009, 113:6392-6402.
71. Foster A.E., Dotti G., Lu A., Khalil M., Brenner M.K., Heslop H.E., Rooney C.M., Bollard C.M. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother 2008, 31:500-505.
72. Brewin J., Mancao C., Straathof K., Karlsson H., Samarasinghe S., Amrolia P.J., Pule M. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood 2009, 114:4792-4803.
73. De Angelis B., Dotti G., Quintarelli C., Huye L.E., Zhang L., Zhang M., Pane F., Heslop H.E., Brenner M.K., Rooney C.M., et al. Generation of Epstein-Barr-virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 2009.
74. Levin L.I., Munger K.L., O'Reilly E.J., Falk K.I., Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010, 67:824-830.
75. Moutschen M., Leonard P., Sokal E.M., Smets F., Haumont M., Mazzu P., Bollen A., Denamur F., Peeters P., Dubin G., et al. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 2007, 25:4697-4705.
76. Sokal E.M., Hoppenbrouwers K., Vandermeulen C., Moutschen M., Leonard P., Moreels A., Haumont M., Bollen A., Smets F., Denis M. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007, 196:1749-1753.
77. Cocco M., Bellan C., Tussiwand R., Corti D., Traggiai E., Lazzi S., Mannucci S., Bronz L., Palummo N., Ginanneschi C., et al. CD34+ cord blood cell-transplanted Rag2-/- gamma(c)-/- mice as a model for Epstein-Barr virus infection. Am J Pathol 2008, 173:1369-1378.
78. Strowig T., Gurer C., Ploss A., Liu Y.F., Arrey F., Sashihara J., Koo G., Rice C.M., Young J.W., Chadburn A., et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med 2009, 206:1423-1434.
79. Shultz L.D., Saito Y., Najima Y., Tanaka S., Ochi T., Tomizawa M., Doi T., Sone A., Suzuki N., Fujiwara H., et al. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc Natl Acad Sci U S A 2010, 107:13022-13027.